Ustekinumab is a fully human IgG1k monoclonal antibody that notably targets the common p40 subunit of IL-12 and IL-23, well-defined key mediators of psoriasis that are able to stimulate two emerging novel CD4 (+) Th-cell subsets, Th17 and Th22, with a crucial role in immune response to tissue inflammation. The gene discussed is IL37; the disease is psoriasis.